ALYACEN 7/7/7 Drug Patent Profile
✉ Email this page to a colleague
When do Alyacen 7/7/7 patents expire, and when can generic versions of Alyacen 7/7/7 launch?
Alyacen 7/7/7 is a drug marketed by Glenmark Pharms Ltd and is included in one NDA.
The generic ingredient in ALYACEN 7/7/7 is ethinyl estradiol; norethindrone. There are twenty-six drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ALYACEN 7/7/7?
- What are the global sales for ALYACEN 7/7/7?
- What is Average Wholesale Price for ALYACEN 7/7/7?
Summary for ALYACEN 7/7/7
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 7 |
| Patent Applications: | 131 |
| DailyMed Link: | ALYACEN 7/7/7 at DailyMed |
US Patents and Regulatory Information for ALYACEN 7/7/7
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glenmark Pharms Ltd | ALYACEN 7/7/7 | ethinyl estradiol; norethindrone | TABLET;ORAL-28 | 091636-001 | Jan 19, 2012 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
